<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079062</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4685-01</org_study_id>
    <nct_id>NCT04079062</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects</brief_title>
  <official_title>Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity in
      Japanese and Caucasian healthy adult male subjects when ONO-4685 is administered as a
      single-dose by intravenous infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity
      when ONO-4685 is administered by single-dose intravenous continuous infusion in Japanese and
      Caucasian healthy adult male subjects. In addition, in Japanese healthy adult male subjects,
      to investigate dosing condition of Keyhole limpet hemocyanin (KLH) and to investigate safety,
      tolerability, pharmacokinetics, pharmacodynamics and immunogenicity when ONO-4685 is
      administered by single-dose intravenous continuous infusion after treating with KLH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events [Safety and Tolerability]</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Number of participants with adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital sign [Safety and Tolerability]</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Summary statistics of blood pressure/pulse rate, respiratory rate, SpO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body temperature [Safety and Tolerability]</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Summary statistics of body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight [Safety and Tolerability]</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Summary statistics of body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG parameter test [Safety and Tolerability]</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Summary statistics of ECG parameter test (Heart Rate, RR, PR, QRS, QT, and QTcF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory test [Safety and Tolerability]</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Summary statistics of laboratory test (hematologic test, blood biochemistry test, blood coagulation test, immunoserologic test urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax [Pharmacokinetic] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Assessment of the Cmax of ONO-4685</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax [Pharmacokinetic] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Assessment of the Tmax of ONO-4685</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC [Pharmacokinetic] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Assessment of the AUC168h, AUClast, and AUCinf of ONO-4685</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 [Pharmacokinetic] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Assessment of the T1/2 of ONO-4685</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL [Pharmacokinetic] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Assessment of the CL of ONO-4685</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss [Pharmacokinetic] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Assessment of the Vss of ONO-4685</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine concentration [Pharmacodynamics] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Serum cytokine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemocyte test [Pharmacodynamics] (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Hemocyte test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (Part B and C)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Anti-KLH antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (PartA, C, and D)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Anti-ONO-4685 antibody</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ONO-4685 (PartA, D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PartA, D)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KLH+placebo (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KLH+ONO-4685 (PartC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KLH+placebo (PartC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ONO-4685</intervention_name>
    <description>Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.</description>
    <arm_group_label>ONO-4685 (PartA, D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by intravenous continuous infusion at the designated speed.</description>
    <arm_group_label>Placebo (PartA, D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH</intervention_name>
    <description>KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.</description>
    <arm_group_label>KLH+placebo (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH, ONO-4685</intervention_name>
    <description>Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.</description>
    <arm_group_label>KLH+ONO-4685 (PartC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH, placebo</intervention_name>
    <description>Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.</description>
    <arm_group_label>KLH+placebo (PartC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese healthy adult male subjects (PartA, B, and C)

          -  Caucasian healthy adult male subjects (Part D)

          -  Age (at the time of informed consent): ≥20 yeas, ≤ 45 yeas

          -  Body weight (at the time of screening test): ≥50 kg

        Exclusion Criteria:

          -  Subjects who are on a treatment for or with a history of respiratory, cardiovascular,
             psychiatric, neurologic, gastrointestinal, immunologic, hepatic, renal, hematopoietic
             or endocrine and/or other disease.

          -  Subjects with current or with a history of severe allergy to drugs or foods

          -  Subjects with current or with a history of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuaki Okamura</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corporate Communications Ono Pharmaceutical Co. Ltd</last_name>
    <email>y.tani@ono.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fukuoka Clinical Site</name>
      <address>
        <city>Hakata</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.ono.co.jp/eng/rd/policy.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

